HROWM SEC Filings

Harrow, Inc. director Adrienne L. Graves bought 1,000 shares of common stock in an open-market transaction at $31.07 per share. This purchase on May 18, 2026 brings her directly held stake to 1,000 shares, indicating a new personal equity position in the company.

Harrow, Inc. director Lauren P. Silvernail purchased 1,000 shares of Harrow common stock in an open-market transaction at $31.00 per share. Following this transaction, Silvernail directly owns 1,000 common shares, indicating this filing reflects an initial reported stake rather than a large position change.

Harrow, Inc. director Lauren P. Silvernail purchased 1,000 shares of Harrow common stock in an open-market transaction at $31.00 per share. Following this transaction, Silvernail directly owns 1,000 common shares, indicating this filing reflects an initial reported stake rather than a large position change.

Shojaei Amir reported acquisition or exercise transactions in this Form 4 filing.

Harrow, Inc. reported that Chief Scientific Officer Amir Shojaei received a grant of 10,000 restricted stock units, each representing a right to one share of common stock. These RSUs vest in full on May 15, 2029, contingent on his continued service, and reflect compensation rather than open-market trading.

Shojaei Amir reported acquisition or exercise transactions in this Form 4 filing.

Harrow, Inc. reported that Chief Scientific Officer Amir Shojaei received a grant of 10,000 restricted stock units, each representing a right to one share of common stock. These RSUs vest in full on May 15, 2029, contingent on his continued service, and reflect compensation rather than open-market trading.

Harrow, Inc.'s Chief Executive Officer Mark L. Baum reported an open-market purchase of 10,000 shares of common stock at a weighted average price of $30.20 per share. After this transaction, he directly owns 2,996,130 shares. The filing notes the shares were bought in multiple trades between $30.18 and $30.34 per share.

Harrow, Inc.'s Chief Executive Officer Mark L. Baum reported an open-market purchase of 10,000 shares of common stock at a weighted average price of $30.20 per share. After this transaction, he directly owns 2,996,130 shares. The filing notes the shares were bought in multiple trades between $30.18 and $30.34 per share.

Harrow, Inc.’s president and CFO, Andrew R. Boll, bought additional company stock. On May 14, 2026, he made open-market purchases totaling 3,500 shares of Harrow common stock at a price of $29.90 per share. After these transactions, he directly owns 814,679 Harrow common shares.

The filing notes the 3,500 shares reflect two separate open-market trades on that date, each executed at $29.90 per share, and indicates that detailed trade information is available upon request.

Harrow, Inc.’s president and CFO, Andrew R. Boll, bought additional company stock. On May 14, 2026, he made open-market purchases totaling 3,500 shares of Harrow common stock at a price of $29.90 per share. After these transactions, he directly owns 814,679 Harrow common shares.

The filing notes the 3,500 shares reflect two separate open-market trades on that date, each executed at $29.90 per share, and indicates that detailed trade information is available upon request.

Harrow, Inc. reported softer results for the quarter ended March 31, 2026. Total revenues were $44.2 million, down from $47.8 million a year earlier, as branded product sales grew but compounding revenues declined sharply, including the prior discontinuation of Klarity-C.

Branded revenue rose to $30.7 million, led by VEVYE at $20.9 million, while IHEEZO sales fell. Compounding revenue dropped to $13.5 million. Higher selling, general and administrative spending and increased R&D pushed the net loss to $27.6 million, compared with $17.8 million in the prior-year quarter.

Harrow ended the quarter with $94.6 million in cash and cash equivalents, helped by issuing an additional $50 million of 8.625% Senior Notes due 2030, bringing total notes payable, net, to $292.1 million. Operating cash flow swung to an outflow of $9.0 million from an inflow of $19.7 million a year earlier.

Harrow, Inc. reported softer results for the quarter ended March 31, 2026. Total revenues were $44.2 million, down from $47.8 million a year earlier, as branded product sales grew but compounding revenues declined sharply, including the prior discontinuation of Klarity-C.

Branded revenue rose to $30.7 million, led by VEVYE at $20.9 million, while IHEEZO sales fell. Compounding revenue dropped to $13.5 million. Higher selling, general and administrative spending and increased R&D pushed the net loss to $27.6 million, compared with $17.8 million in the prior-year quarter.

Harrow ended the quarter with $94.6 million in cash and cash equivalents, helped by issuing an additional $50 million of 8.625% Senior Notes due 2030, bringing total notes payable, net, to $292.1 million. Operating cash flow swung to an outflow of $9.0 million from an inflow of $19.7 million a year earlier.

Harrow, Inc. ownership update: a joint Schedule 13G/A shows Opaleye entities and James Silverman report beneficial ownership of 2,832,230 shares of Harrow common stock. The filing states this equals 7.61% of the class. Opaleye, L.P. separately reports 2,805,000 shares (7.53%), based on 37,229,705 shares outstanding as of February 25, 2026.

The statement clarifies shared voting and dispositive power over the reported shares and is signed by James Silverman on behalf of all reporting persons.

Harrow, Inc. ownership update: a joint Schedule 13G/A shows Opaleye entities and James Silverman report beneficial ownership of 2,832,230 shares of Harrow common stock. The filing states this equals 7.61% of the class. Opaleye, L.P. separately reports 2,805,000 shares (7.53%), based on 37,229,705 shares outstanding as of February 25, 2026.

The statement clarifies shared voting and dispositive power over the reported shares and is signed by James Silverman on behalf of all reporting persons.

Harrow, Inc. reported first-quarter 2026 revenue of $44.2 million, down 8% from $47.8 million a year earlier, mainly due to VEVYE gross-to-net adjustments and softer compounded product sales. Gross margin declined to 61% from 68%, and the company posted a net loss of $27.6 million, wider than the prior-year loss of $17.8 million. Adjusted EBITDA was a loss of $12.7 million versus a $2.0 million loss last year, reflecting heavier commercial and R&D investment.

Despite weaker reported earnings, demand for key brands remained strong. VEVYE generated $20.9 million in revenue after an estimated $8 million non-recurring gross-to-net reduction and achieved about 14% branded dry eye market share, surpassing XIIDRA on monthly total prescriptions. IHEEZO unit demand rose 18% year over year, and TRIESENCE demand more than doubled, marking a sixth straight growth quarter.

Harrow ended the quarter with $94.6 million in cash and reiterated its full-year 2026 guidance for revenue of $350–$365 million and Adjusted EBITDA of $80–$100 million, with performance weighted to the second half. Second-quarter 2026 revenue is expected between $71 million and $81 million, supported by an expanded sales force, growing prescription trends for VEVYE, and increasing adoption of IHEEZO and TRIESENCE.

Harrow, Inc. reported first-quarter 2026 revenue of $44.2 million, down 8% from $47.8 million a year earlier, mainly due to VEVYE gross-to-net adjustments and softer compounded product sales. Gross margin declined to 61% from 68%, and the company posted a net loss of $27.6 million, wider than the prior-year loss of $17.8 million. Adjusted EBITDA was a loss of $12.7 million versus a $2.0 million loss last year, reflecting heavier commercial and R&D investment.

Despite weaker reported earnings, demand for key brands remained strong. VEVYE generated $20.9 million in revenue after an estimated $8 million non-recurring gross-to-net reduction and achieved about 14% branded dry eye market share, surpassing XIIDRA on monthly total prescriptions. IHEEZO unit demand rose 18% year over year, and TRIESENCE demand more than doubled, marking a sixth straight growth quarter.

Harrow ended the quarter with $94.6 million in cash and reiterated its full-year 2026 guidance for revenue of $350–$365 million and Adjusted EBITDA of $80–$100 million, with performance weighted to the second half. Second-quarter 2026 revenue is expected between $71 million and $81 million, supported by an expanded sales force, growing prescription trends for VEVYE, and increasing adoption of IHEEZO and TRIESENCE.

Harrow, Inc. is asking stockholders to vote on directors, executive pay and its auditor at the 2026 annual meeting. The meeting will be held on June 18, 2026 at 8:00 a.m. Central Time at the Nashville headquarters, for holders of record as of April 21, 2026.

Stockholders are being asked to elect four directors, approve on an advisory basis the compensation of named executive officers, and ratify Deloitte & Touche LLP as independent auditor for 2026. Three of four director nominees are independent, and all standing committees are fully independent, with a Lead Independent Director providing additional oversight.

The proxy describes a pay‑for‑performance program. In 2025, bonuses for key executives, including CEO Mark Baum and President/CFO Andrew Boll, were paid at target levels based on revenue growth, adjusted EBITDA, product performance and debt refinancing. Baum and Boll also received multi‑year performance stock units tied to ambitious stock‑price hurdles between $50 and $100 per share.

Harrow, Inc. is asking stockholders to vote on directors, executive pay and its auditor at the 2026 annual meeting. The meeting will be held on June 18, 2026 at 8:00 a.m. Central Time at the Nashville headquarters, for holders of record as of April 21, 2026.

Stockholders are being asked to elect four directors, approve on an advisory basis the compensation of named executive officers, and ratify Deloitte & Touche LLP as independent auditor for 2026. Three of four director nominees are independent, and all standing committees are fully independent, with a Lead Independent Director providing additional oversight.

The proxy describes a pay‑for‑performance program. In 2025, bonuses for key executives, including CEO Mark Baum and President/CFO Andrew Boll, were paid at target levels based on revenue growth, adjusted EBITDA, product performance and debt refinancing. Baum and Boll also received multi‑year performance stock units tied to ambitious stock‑price hurdles between $50 and $100 per share.

Harrow Inc: Amendment No. 1 to a Schedule 13G/A was filed reporting that The Vanguard Group beneficially owns 0 shares of Harrow Inc common stock after an internal realignment effective January 12, 2026.

The filing explains that certain Vanguard subsidiaries or business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The statement is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.

Harrow Inc: Amendment No. 1 to a Schedule 13G/A was filed reporting that The Vanguard Group beneficially owns 0 shares of Harrow Inc common stock after an internal realignment effective January 12, 2026.

The filing explains that certain Vanguard subsidiaries or business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The statement is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.